K-ras point mutations in endometrial carcinoma: Effect on outcome is dependent on age of patient

Gynecologic Oncology

Volumn 63, Issue 2, 1996, Pages 238-246

  Ito, Kiyoshi ^a   Watanabe, Keiko ^a   Nasim, Suhail ^c   Sasano, Hironobu ^b   Sato, Shinji ^a   Yajima, Akira ^a   Silverberg, Steven G ^d   Garret, Carleton T ^c,d  

^a Dept of Obstetrics and Gynecology ^*  (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; FEMALE; GENE ACTIVATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; ONCOGENE K RAS; POINT MUTATION; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030298517     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0313     Document Type: Article

References (49)

1. 1. Ries, L. A. G., Hankey, B. F., Miller, B. A., Hartman, A. M., and Edwards, B. K. Cancer Statistics Review, 1973-1988, NIH Pub. No. 91-2789, National Cancer Institute (1991).
2. 2. Sasaki, H., Nishii, H., Takahashi, H., Tada, A., Furusato, M., Terashima, Y., Siegal, G. P., Parker, S. L., Kohler, M. F., Berchuck, A., and Boyd, J. Mutation of the K-ras proto-oncogene in human endometrial hyperplasia and carcinoma, Cancer Res. 53, 1906-1910 (1993).
3. 3. Enomoto, T., Inoue, M., Perantoni, A. O., Buzard, G. S., Miki, H., Tanizawa, O., and Rice, J. M. K-ras activation in premalignant and malignant epithelial lesions of the human uterus, Cancer Res. 51, 5308-5314 (1991).
4. 4. Enomoto, T., Fugita, M., Inoue, M., Rice, J. M., Nakajima, R., Tanizawa, O., and Nomua, T. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 proto-oncogene in premalignant and malignant lesions of the human uterine endometrium, Cancer Res. 53, 1883-1888 (1993).
5. 5. Duggan, B. D., Felix, J. C., Muderspach, L. I., Tsao, J. L., and Shibata, D. K. Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma, Cancer Res. 54, 1604-1607 (1994).
6. 6. Mizuuchi, H., Nasim, S., Kudo, R., Silverberg, S. G., Greenhouse, S., and Garrett, C. T. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium, Cancer Res. 52, 2777-2781 (1992).
7. 7. Fujimoto, I., Shimizu, Y., Hirai, Y., Chen, J. T., Teshima, H., Hasumi, K., Masubuchi, K., and Takahashi, M. Studies on ras oncogene activation in endometrial carcinoma, Gynecol. Oncol. 48, 196-202 (1993).
8. 8. Sato, S., Ito, K., Ozawa, N., Yajima, A., and Sasano, H. Analysis of point mutations at codon 12 of K-ras in human endometrial carcinoma and cervical adenocarcinoma by dot blot hybridization and polymerase chain reaction, Tohoku J. Exp. Med. 165, 131-136 (1991).
9. 9. Caduff, R. F., Johnston, C. M., and Frank, T. S. Mutations of the Ki-ras oncogene in carcinoma of the endometrium, Am. J. Pathol. 146, 182-188 (1995).
10. 10. Kauppila, A., Gronroos, M., and Nieminen, U. Clinical outcome in endometrial cancer, Obstet. Gynecol. 60, 473-480 (1982).
11. 11. Lurain, J. R., Rice, B. L., Rademaker, A. W., Poggensee, L. E., Schink, J. C., and Miller, D. S. Prognostic factors associated with recurrent in clinical stage I adenocarcinoma of the endometrium, Obstet. Gynecol. 78, 63-69 (1991).
12. 12. Lindahl, B., Ranstam, J., and Willen, R. Five year survival rate in endometrial carcinoma stages I-II: Influence of degree of tumor differentiation, age, myometrial invasion and DNA content, Br. J. Obstet. Gynecol. 101, 621-625 (1994).
13. 13. Connelly, P. J., Alberhasky, R. C., and Chistopherson, W. M. Carcinoma of the endometrium: Analysis of 865 cases of adenocarcinoma and adenoacanthoma, Obstet. Gynecol. 59, 569-574 (1982).
14. 14. Scully, R. E., Bonfiglio, T. A., Kurman, R. R., Silverberg, S. G., and Wilkinson, E. J. WHO International Classification of Tumors: Histological Typing of Female Genital Tract Tumours, 2nd ed., Springer-Verlag, Berlin (1994).
15. 15. Sasano, H., Garrett, C. T., Wilkinson, D. S., Silverberg, S. G., Comerfold, J., and Hyde, J. Proto-oncogene amplification and tumor ploidy in human ovarian neoplasms, Hum. Pathol. 21, 382-391 (1990).
16. 16. Jiang, W., Kahn, S. M., Guillem, J. G., Lu, S-H., and Weinstein, I. B. Rapid detection of ras oncogenes in human tumors: Applications to colon, esophageal and gastric cancer, Oncogene 4, 923-928 (1989).
17. 17. Kahn, H. A., and Sempos, C. T., Statistical Methods in Epidemiology, Oxford Univ. Press, New York (1989).
18. 18. Stata. Statistics/Graphics/Data/Management, release 3.0, Computing Resources Center, Santa Monica, CA (1993).
19. 19. Cox, D. R. Regression models and life tables, J.R. Stat. Soc. Soc. B 34, 187-202 (1972).
20. 20. Masubuchi, S., Fujimoto, I., and Msubuchi, K. Lymph node metastasis and prognosis of endometrial carcinoma, Gynecol. Oncol. 7, 36-46 (1979).
21. 21. Beckner, M. E., Mori, T., and Silverberg, S. G. Endometrial carcinoma: Non-tumor factors in prognosis, Int. J. Gynecol. Pathol. 4, 131-145 (1985).
22. 22. Bokhman, J. V. Two pathogenetic types of endometrial carcinoma, Gynecol. Oncol. 15, 10-17 (1983).
23. 23. Deligdish, L., and Holinka, C. F. Endometrial carcinoma: Two diseases?, Cancer Detect. Prevent. 10, 237-246 (1987).
24. 24. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, Cell 53, 549-554 (1988).
25. 25. Bos, J. L. The ras gene family and human carcinogenesis, Mutat. Res. 195, 255-271 (1988).
26. 26. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M. M., and Bos, J. L. Genetic alterations during colorectal-tumor development, N. Engl. J. Med. 319, 525-532 (1988).
27. 27. Slebos, R. J. C., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C. J. L. M., Wagenaar, S-S., Vanderschueren, R. G. J. R. A., Van Zandwijk, N., Mooi, W. J., Bos, J. L., and Rodenhuis, S. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung, N. Engl. J. Med. 323, 561-565 (1990).
28. 28. Rodenhuis, S., and Slebos, R. J. C. Clinical significance of ras oncogene activation in human lung cancer, Cancer Res. 52, 2665-2669 (1992).
29. 29. Mitsudomi, T., Steinbwerg, S. M., Oie, H. K. K., Mulshine, J. L., Phelps, R., Viallet, J., Pass, H., Minna, J. D., and Gazdar, A. F. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent, Cancer Res. 51, 4999-5002 (1991).
30. 30. Scambia, G., Catozzi, L., Benedetti-Panici, P., Ferrandina, G., Battaglia, F., Giovannini, G., Distefano, M., Pellizzola, D., Piffanelli, A., and Mancuso, S. Expression of ras p21 oncoprotein in normal and neoplastic human endometrium, Gynecol. Oncol. 50, 339-346 (1993).
31. 31. DeBortoli, M. E., Abou-Issa, H., Haley, B. E., and Cho-Chung, Y. S. Amplified expression of p21 ras protein in hormone-dependent mammary carcinomas of humans and rodents, Biochem. Biophys. Res. Commun. 127, 699-706 (1985).
32. 32. Fujimoto, J., Hori, M., Ichigo, S., Nishigaki, M., and Tamaya, T. S. Tissue differences in the expression of mRNAs of Ha-ras, c-myc, fos and jun in human uterine endometrium, myometrium and leiomyoma under the influence of estrogen/progesterone, Tumour Biol. 15, 311-317 (1994).
33. 33. Planchon, P., Magnien, V., Starzec, A., and Prevost, G. Selection of a highly tumorigenic breast cancer cell line sensitive to estradiol to evidence in vivo the tumor-inhibitory effect of butyrate derivative Monobut-3, Life Sci. 55, 951-959 (1994).
34. 34. Tiwari, R. K., Mukhopadhyay, B., Telang, N. T., and Osborne, M. P. Modulation of gene expression by selected fatty acids in human breast cancer cells, Anticancer Res. 11, 1383-1388 (1991).
35. 35. Kasid, A., and Lippman, M. E. Estrogen and oncogene mediated growth regulation of human breast cancer cells, J. Steroid Biochem. 27, 465-470 (1987).
36. 36. Lundy, J., Grimson, R., Mishriki, Y., Chao, S., Oravez, S., Fromowitz, F., and Viola, M. V. Elevated ras oncogene expression correlates with lymph node metastases in breast cancer patients, J. Clin. Oncol. 4, 1321-1325 (1986).
37. 37. Yaginuma, Y., Fujita, M., Saitoh, S., Hayakawa, K., Kuzumaki, N., and Ishikawa, M. Immunohistochemical analysis of ras oncogene product p21 in human endometrial carcinoma, Acta Histochem. 95, 23-29 (1993).
38. 38. Tornos, C., Silva, E. G., el-Naggar, A., and Burke, T. W. Aggressive stage I grade 1 endometrial carcinoma, Cancer 70, 790-798 (1992).
39. 39. Celano, P., Berchtold, C. M., Mabry, M., Carroll, M., Sidransky, D., Casero, R. A., Jr., and Lupu, R. Induction of markers of normal differentiation in human colon carcinoma cells by the v-rasH oncogene, Cell Growth Differ. 4, 341-347 (1993).
40. 40. Augenlicht, L. H., Augeron, C., Yander, G., and Laboisse, C. Overexpression of ras in mucus-secreting human colon carcinoma cells of low tumorigenicity, Cancer Res. 47, 3763-3765 (1987).
41. 41. Kurman, R. J., Zaino, R. J., and Norris, H. J. Endometrial carcinoma, in Blaustein's Pathology of the Female Genital Tract (R. J. Kurman, Ed.), 4th ed., pp. 439-483, Springer-Verlag, New York, (1994).
42. 42. Parazzini, F., La Vecchia, C., Bocciolone, L., and Franceschi, S. The epidemiology of endometrial cancer, Gynecol. Oncol. 41, 1-16 (1991).
43. 43. The Research Group for Population-Based Cancer Registration in Japan. Cancer incidence in Japan, in Cancer Mortality and Morbidity Statistics - Japan and the World - 1994 (S. Tominaga, K. Aoki, I. Fujimoto, and M. Kurihara, Eds.), pp. 107-158, Japan Sci. Soc., Tokyo, and CRC Press, Boca Raton, FL (1994).
44. 44. Silverberg, S. G., Sasano, N., and Yajima, A. Endometrial carcinoma in Miyagi Prefecture, Japan: Histopathologic analysis of a cancer registry-based series and comparison with cases in American women, Cancer 49, 1504-1510 (1982).
45. 45. Kuroishi, T., Hirose, K., Tajima, K., and Tominaga, S. Cancer mortality in Japan (1950-1990), in Cancer Mortality and Morbidity Statistics - Japan and the World - 1994 (S. Tominaga, K. Aoki, I. Fujimoto, and M. Kurihara, Eds.), pp. 1-106, Japan Sci. Soc., Tokyo, and CRC Press, Boca Raton, FL (1994).
46. 46. Masubuchi, K., Masubuchi, S., Suzumura, H., Kubo, H., Okajima, H., Ogiuchi, M., Kim, C. D., Chen, H. F., Yamauchi, K., and Hattori, K. Cancer of the uterine cervix and endometrium at the Cancer Institute Hospital, Tokyo, in Recent Results of Cancer Treatment in Japan (T. Kajitani, Y. Koyama, and Y. Umegaki, Eds.), pp. 127-136, Japan Sci. Soc., Tokyo, and University Park Press, Baltimore (1979).
47. 47. Enomoto, T., Fujita, M., Inoue, M., Nomura, T., and Shroyer, K. R. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado, Am. J. Clin. Pathol. 103, 224-230 (1995).
48. 48. Kaku, T., Silverberg, S. G., Tsukamoto, N., Tsuruchi, N., Kamura, T., Saito, T., and Nakano, H. Association of endometrial epithelial metaplasias with endometrial carcinoma and hyperplasia in Japanese and American women, Int. J. Gynecol. Pathol. 12, 297-300 (1993).
49. 49. Kaku, T., Tsukamoto, N., Hachisuga, T., Tsuruchi, N., Sakai, K., Hirakawa, T., Amada, S., Saito, T., Kamura, T., and Nakano, H. Endometrial carcinoma associated with hyperplasia, Gynecol. Oncol. 60, 22-25 (1996).